BEIGENE (rebranded globally as BeOne Medicines) reported a year-of-inflection 2025, delivering its first GAAP net profit and positive operating cash flow since listing.

• Revenue jumped 40% year on year to USD 5.34 billion, powered by oncology flagship BRUKINSA, which generated USD 3.90 billion, up 49%.

• GAAP profitability was achieved ahead of schedule; specific earnings figures were not disclosed. Management highlighted “meaningful” cash generation and an expanded cash position.

• During 2025 the group completed its redomiciliation to Switzerland and adopted the BeOne Medicines brand, now employing nearly 12,000 staff across six continents.

• Pipeline momentum: sonrotoclax received its first global approval, a U.S. FDA filing for R/R mantle-cell lymphoma is expected in 1H 2026, and BTK CDAC degrader BGB-16673 targets accelerated approval in 2027.

• R&D focus: five solid-tumour programmes are slated to reach registration-enabling trials in 2026, while expanded AI use is shortening protocol development and site-monitoring timelines.

• Capital resources: management said the strengthened balance sheet and ongoing cash generation position the group for additional business-development transactions.

• Governance: the 2026 AGM is set for 11 June 2026 in Zurich; shareholders will vote on 20 resolutions, including re-election of directors and refreshed equity plans that raise the option pool by 75.40 million shares and the ESPP reserve by 3.25 million shares.

The company reiterated its ambition to build the leading global oncology franchise, citing more than two million patients treated with its medicines to date.